(PR-inside.com) TUSTIN, CA -- (Marketwire) -- 09/20/11 -- Radient Pharmaceuticals Corporation "the Company" or "Radient" (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it has submitted two scientific abstracts to the American Society of Clinical Oncologists (ASCO). Both abstracts discussed the results of recent studies on the monitoring and screening of colorectral cancer using Onko-Sure® in conjunction with carcinoembryonic antigen (CEA). When Onko-Sure® was used in conjunction with CEA, the sensitivity was 55% higher compared to that of using CEA alone. Upon acceptance of these abstracts by ASCO, they will be presented ..
More...
More...